161058-83-9

NU 2058 is an inhibitor of cyclin-dependent kinase 1 (Cdk1) and Cdk2 (IC₅₀s = 7.0 and 17 μM, respectively). Increased Cdk activity is often associated with human tumors, and inhibitors of Cdks, including NU 2058, can arrest cell cycling in cancer cells in vitro.

Competitive inhibitor of CDK1/cyclin B (IC50=5μM) and CDK2/cyclin A (IC50=12μM). Pharmacologically distinct from the relative specific inhibitor of CDK1/2 roscovitine .

Cyclin-dependent kinase (cdk) 1 and cdk2 inhibitor (K i values are 5 and 12 μ M respectively). Inhibits growth of human tumor cells in vitro (mean GI 50 = 13 μ M). Also inhibits DNA topoisomerase II ATPase activity (IC 50 = 300 μ M).

CDK1: 26 μM (IC₅₀); CDK2: 17 μM (IC₅₀); CDK2: 12 μM (Ki)

Store at +4°C

[1] IAN R. HARDCASTLE. N2-Substituted O6-Cyclohexylmethylguanine Derivatives: Potent Inhibitors of Cyclin-Dependent Kinases 1 and 2[J]. Journal of Medicinal Chemistry, 2004, 47 15: 3710-3722. DOI: 10.1021/jm0311442
[2] ROGER J. GRIFFIN  et al. et al. Structure-Based Design of 2 -Arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine Inhibitors of Cyclin-Dependent Kinases 1 and 2.[J]. ChemInform, 2003, 34 51. DOI: 10.1002/chin.200351143
[3] N JOHNSON. Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells[J]. British Journal of Cancer, 2009, 102 2: 342-350. DOI: 10.1038/sj.bjc.6605479
[4] A C RIGAS  N J C  C N Robson. Therapeutic potential of CDK inhibitor NU2058 in androgen-independent prostate cancer[J]. Oncogene, 2007, 26 55: 7611-7619. DOI: 10.1038/sj.onc.1210586